Functional specificity of Akt isoforms in cancer progression

Related Experiment Video

Updated: Apr 12, 2026

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.7K

Anne-Marie Fortier, Eric Asselin, Monique Cadrin

    Biomolecular Concepts
    |May 12, 2015
    PubMed

    Insights

    Hyperactivation of Akt signaling drives cancer progression. Targeting specific Akt isoforms (Akt1, Akt2, Akt3) is crucial for developing effective anticancer drugs against various carcinomas and melanomas.

    Area of Science:

    • Molecular Biology
    • Oncology
    • Biochemistry

    Background:

    • Akt/Protein Kinase B (PKB) kinases are critical regulators of cellular homeostasis.
    • Hyperactivation of Akt signaling pathways is a significant factor in human cancer progression, influencing tumor growth, chemoresistance, and metastasis.
    • Understanding the distinct roles of the three Akt isoforms (Akt1, Akt2, Akt3) is essential for deciphering their specific contributions to cancer development.

    Purpose of the Study:

    • To elucidate the differential roles of Akt1, Akt2, and Akt3 isoforms in various human cancers.
    • To explore the mechanisms by which Akt isoforms exert distinct or opposing effects in cancer cells.
    • To highlight the necessity of isoform-specific targeting for effective anticancer drug development.

    Main Methods:

    • Review and synthesis of existing literature on Akt isoform function in cancer.
    • Analysis of Akt isoform expression patterns and alterations in different cancer types.
    • Examination of proposed mechanisms for differential Akt isoform activity, including tissue-specific expression, substrate specificity, and localization.

    Main Results:

    • Akt1 is predominantly implicated in tumor growth, invasion, and chemoresistance across various carcinomas.
    • Akt2 is primarily associated with cancer cell invasion, metastasis, and survival, with alterations frequently observed in breast, ovarian, pancreatic, and colorectal cancers.
    • Akt3's role is more restricted, mainly contributing to tumor growth and drug resistance in melanomas, gliomas, and some breast cancers.

    Conclusions:

    • The specific Akt isoform involved dictates its role in cancer progression, necessitating consideration of individual isoform functions.
    • Mechanisms such as tissue-specific expression, distinct substrate interactions, and cytoskeletal localization contribute to the differential roles of Akt isoforms.
    • Developing effective Akt inhibitor drugs requires targeting the specific isoform driving a particular tumor's progression.

    More Related Videos

    Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

    Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

    Published on: June 9, 2023

    2.5K
    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    930

    Related Concept Videos

    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    5.1K
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    1.7K
    PI3K/mTOR/AKT Signaling Pathway01:22

    PI3K/mTOR/AKT Signaling Pathway

    The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
    6.5K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
    Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
    7.5K
    Adaptive Mechanisms in Cancer Cells02:53

    Adaptive Mechanisms in Cancer Cells

    4.3K
    Inhibition of Cdk Activity02:34

    Inhibition of Cdk Activity

    The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
    6.2K